Tag
USFDA
3 articles
Cipla's InvaGen USFDA Inspection Gets NAI Classification
Cipla discloses USFDA classified its InvaGen subsidiary's Hauppauge facility inspection as No Action Indicated (NAI).
The inspection occurred from 19-22 October 2026, with the NAI classification commu
Alembic Pharma USFDA Binimetinib Final Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Binimetinib Tablets, 15 mg and 45 mg.
The product has an estimated market size of US$282 million and the company is eligible for 1
Dr. Reddy's USFDA Bachupally Facility Gets VAI Classification
Dr. Reddy's discloses USFDA inspection outcome for its Bachupally formulations facility as 'Voluntary Action Indicated' (VAI).
The USFDA has officially closed the inspection under regulation 21 CFR 20